Pharmafile Logo
Pharmafocus logo
Advanced Search

Vesper Bio

Showing 1 posts of 1 posts found.

Vesper Bio reports positive topline results for dementia candidate

November 7, 2025
Research and Development Frontotemporal degeneration, Vesper Bio, clinical trials, dementia

Vesper Bio, a clinical-stage biotech developing novel oral therapies for neurodegenerative and neuropsychiatric disorders, has reported positive topline data from …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026